Antengene Corporation Ltd
HKEX:6996
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antengene Corporation Ltd
Cash & Cash Equivalents
Antengene Corporation Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Cash & Cash Equivalents
¥733.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash & Cash Equivalents
¥31.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash & Cash Equivalents
¥40.9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
27%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash & Cash Equivalents
¥9.1B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash & Cash Equivalents
¥7.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash & Cash Equivalents
¥5.1B
|
CAGR 3-Years
73%
|
CAGR 5-Years
158%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
733.9m
CNY
Based on the financial report for Dec 31, 2025, Antengene Corporation Ltd's Cash & Cash Equivalents amounts to 733.9m CNY.
What is Antengene Corporation Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-25%
Over the last year, the Cash & Cash Equivalents growth was -55%. The average annual Cash & Cash Equivalents growth rates for Antengene Corporation Ltd have been -26% over the past three years , -25% over the past five years .
